20Jul 2026

UGI USER
CDSCO fatty liver disease India health news liver disease treatment MASH medical approval India NASH Semaglutide UPSC Current Affairs Wegovy
7
0

CDSCO Approves Wegovy for MASH Fatty Liver Disease

CDSCO APPROVES WEGOVY FOR TREATMENT OF MASH (FATTY LIVER DISEASE) Why in the News? Regulatory Approval: The Central Drugs Standard Control Organisation (CDSCO) has approved Wegovy (Semaglutide 2.4 mg) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in adults, reflecting India’s participation in global pharmaceutical strategic competition. First-of-Its-Kind Therapy: It is the first injectable GLP-1 …

SEMAGLUTIDE GENERICS EXPAND INDIA’S GLP-1 DRUG MARKET

SEMAGLUTIDE GENERICS EXPAND INDIA’S GLP-1 DRUG MARKET Why in the News? The launch of generic versions of semaglutide has led to a 75% rise in sales of GLP-1 drugs in India within one month. Sales volume of semaglutide increased from 25,000 units in February to 1.7 lakh units in April 2026 after patent expiry of …

Semaglutide May Reduce Alzheimer’s Risk in Diabetics

Why in the news? A new study suggests that semaglutide, a drug for type 2 diabetes and weight loss, may significantly reduce Alzheimer’s risk. This potential breakthrough offers a novel approach to dementia prevention alongside diabetes management, especially for high-risk populations. Study Overview and Findings: Semaglutide, the active ingredient in popular drugs for type 2 …

Tag

CDSCO Approves Wegovy for MASH Fatty Liver Disease

SEMAGLUTIDE GENERICS EXPAND INDIA’S GLP-1 DRUG MARKET

Semaglutide May Reduce Alzheimer’s Risk in Diabetics

Two Mega Events, One Extraordinary Platform at Universal Green School